Immunovant Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-464.2	-413.84	-259.34	-210.96	-156.73	-107.43
Depreciation & Amortization	0.42	0.38	0.23	0.19	0.13	0.07
Stock-Based Compensation	56.27	49.49	41.12	32.3	34.24	18.82
Other Operating Activities	0.1	0.13	1.13	1.13	1.11	0.65
Change in Accounts Receivable	0.51	3.23	-4.58	11.76	-11.63	-0.6
Change in Accounts Payable	-11.21	10.68	5.78	-17.12	16.25	1.25
Change in Income Taxes	-0.26	-0.26	0.02	0.46	-0.09	-0.51
Change in Other Net Operating Assets	-4.52	-25.69	1.41	-5.95	10.61	4.42
Operating Cash Flow	-422.89	-375.87	-214.23	-188.19	-106.11	-83.33
Capital Expenditures	-0.2	-0.76	-0.36	-0.2	-0.25	-0.21
Investing Cash Flow	-0.2	-0.76	-0.36	-0.2	-0.25	-0.21
Short-Term Debt Repaid	-	-	-	-	-	-3.19
Total Debt Repaid	-	-	-	-	-	-3.19
Net Debt Issued (Repaid)	-	-	-	-	-	-3.19
Issuance of Common Stock	1,044	454.81	478.44	71.16	200.13	387.54
Other Financing Activities	-0.91	-0.32	-6.01	-0.27	-	-1.24
Financing Cash Flow	1,043	454.49	472.43	70.89	200.13	383.11
Foreign Exchange Rate Adjustments	0.2	0.75	0.99	0.22	-0.09	-
Net Cash Flow	619.84	78.61	258.83	-117.29	93.67	299.58
Free Cash Flow	-423.09	-376.63	-214.59	-188.39	-106.37	-83.54
Free Cash Flow Per Share	-2.44	-2.48	-1.55	-1.53	-0.97	-0.95
Cash Income Tax Paid	3.34	1.2	0.51	-	-	0.17
Levered Free Cash Flow	-260.59	-227.82	-124.15	-107.82	-47.88	-43.79
Unlevered Free Cash Flow	-260.59	-227.82	-124.15	-107.82	-47.88	-43.79
Change in Working Capital	-15.48	-12.03	2.63	-10.85	15.14	4.57

Updated Feb 6, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q